Welcome to
Chemical Collective

Are you 18 or older?

Please confirm that your are 18 years of age or older.

You are not allowed to access the page.

I am 18+

EXIT

SALE NOW ON!

PSYCH NEWS – 17/11/25

By David Blackbourn

LSD and Major Depressive Disorder
Robert F. Kennedy Jr. Smokes DMT?
25C-NBF is a Rapid Antidepressant
Not Just a Running Documentary: Dante
Psychedelic Therapy: Edge of Life
Psilocybin More Than Medicine?
Psychedelics and Neuroplasticity
Methylone and PTSD
The Trump Administration Embraces Psychedelic Therapy
Harvard Law School Debates Legalisation

8 minute read

0 Last updated November 17th, 2025

By David Blackbourn

Disclaimer: The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Chemical Collective or any associated parties.

This Psych News we’ve more major developments in science, politics and finance. A new study has found that microdosing LSD is effective at tackling symptoms of major depressive disorder. Another study has identified another potential antidepressant substance, 25C-NBF. Further research into psychedelics’ effects on neuroplasticity (the brain’s ability to change) has challenged long-held theories.

In the political sphere, top Trump administration officials have attended a MAHA summit with a panel dedicated solely to psychedelic medicine. Concurrently, a Harvard Law School panel has been debating the potential impact of federal legalisation. This all comes as Health Secretary Robert F. Kennedy Jr. has faced public allegations of drug use, including the use of smoked DMT.

Two new documentaries are broadening the current public conversation on psychedelic use. Edge of Life explores shamanic means of end-of-life care in the Amazon, while Dante follows an ultramarathoner’s 500-mile run, fueled throughout by psychedelics. Conversely to this, a mother’s public admission of microdosing throughout pregnancy has bred controversy, alongside growing debate as to whether or not psychedelics should be treated solely as medication, or whether they have value recreationally.

LSD and Major Depressive Disorder

Researchers at the University of Auckland in New Zealand have shown that microdosing LSD may potentially offer significant relief for people struggling with major depressive disorder. The study consisted of 19 volunteers and aimed to find a more effective treatment than traditional antidepressants. Antidepressants come with a whole host of negative side-effects, are slow to take effect and simply fail to help a large proportion of patients. Many of the participants were already prescribed antidepressants, which had failed to adequately manage their symptoms. The study tasked them with self-administering 16 doses of LSD over 8 weeks. The dose gradually increased throughout the study, from 6mg to 20mg.

The results showed a profound reduction in participants’ depressive symptoms. This reduction also appeared long-lasting. At the end of the 8-week period, participants’ depression scores (measured on the MADRS scale) had dropped by around 60% across the board. Nine of the participants even met the criteria for full remission of their symptoms. Alongside that, anxiety scores dropped by over 50%, while rumination on negative thoughts also decreased by 15%. Participants also reported a perceived better overall quality of life. These changes appeared to continue for at least 6 months following the microdosing regimen.

No serious side effects were reported. The only minor negative effect seemed to be headache, which two participants recorded. One participant withdrew from the study due to anxiety on dosing days. As ever, the researchers concluded that while the results show definite therapeutic potential, there is a need for much more research, at a much larger scale.

Robert F. Kennedy Jr. Smokes DMT?

An upcoming memoir by the journalist Olivia Nuzzi has alleged that current US Health Secretary, Robert F. Kennedy Jr., has secretly used psychedelic drugs for years. This comes despite his decades-long claims of sobriety. The allegation is detailed in Nuzzi’s American Canto, in which she claims to have had a several-month-long “digital-only relationship” with the married Kennedy.

In the book, Nuzzi is said to claim that Kennedy confided in her his use of smoked DMT (dimethyltryptamine). Kennedy has claimed sobriety publicly since a 1983 arrest for heroin use. Their relationship is said to have begun following a profile on Kennedy, which Nuzzi wrote for New York magazine. Kennedy denies this, but has yet to respond to any other allegations.

Kennedy’s psychedelic use is possibly made more plausible due to the fact that, in recent years, he has been campaigning hard for the use of psychedelics in a therapeutic context for depression and trauma.

25C-NBF is a Rapid Antidepressant

A new study, published in Molecular Psychiatry, has identified a new psychedelic phenethylamine, 25C-NBF. The substance has been shown to promote rapid antidepressant effects in rodents. This is combined with a seemingly excellent safety profile. The researchers were seeking potential, effective alternatives to well-known phenethylamines, like amphetamine or methamphetamine, which can carry a high risk of abuse. A single dose of 25C-NBF was shown to reverse depressive behaviours in mice subjected to acute stress. These effects appeared within 24 hours, and during the stress test, the effects continued for at least a week.

Researchers believe the therapeutic effects are a result of the “psychoplastogenic” properties of the substance. 25C-BNF, like many other psychedelics, appears to enhance the brain’s neuroplasticity. This is seen in more detail here, with 25C-BNF promoting structural neural plasticity – basically, promoting new growth. This growth was seen largely in the prefrontal cortex, the part of the brain largely responsible for executive functions – decision making/problem solving, etc. This is a mechanism it shares with other psychedelics with fast-acting antidepressant effects, such as ketamine and psilocybin.

Most importantly, 25C-BNF appears to show no rewarding or reinforcing effects when considering its abuse potential. This is likely due to its selectivity of effects, as, unlike most other phenethylamines, it does not increase dopamine levels in the brain’s reward centre. These findings suggest the substance and its subsequent analogues may represent an entirely new class of antidepressants.

Not Just a Running Documentary: Dante

A new documentary called Dante details the extraordinary 500-mile, 11-day run of Dante Liberato, a 27-year-old, retired MMA fighter. Dante ran from his gym in Manitou, Colorado, to Moab in Utah, consuming LSD and psilocybin mushrooms for the entire journey. The run, which was followed by a camera crew and support team, is what Dante calls a “bridge” to a more self-aware society. Liberato already integrates psychedelics into his lifestyle and promotes this on his Instagram. His gym blends fight training with mindfulness practices using a psilocybin dosing app called Couchmilk. He claims (though I have, if I’m honest, not checked this) that every fighter who has undergone his program is undefeated.

Dante states that any industry sponsors were immediately “out” as soon as psychedelics were mentioned. That only increased his motivation. The documentary aims to destigmatise the use of psychedelics in this context. Dante believes they can act as a performance enhancer. He says the film is not just a “running documentary”. It is designed to shake up the community and show that the stereotype of “sitting around tripping” is a falsehood. The documentary emphasises harm reduction and responsible use.

Psychedelic Therapy: Edge of Life

Edge of Life is another new documentary, this time focusing on Australian artist and filmmaker Lynette Wallworth, as she explores alternative approaches to end-of-life care. Wallworth experienced a near-death experience at the age of 11 and, as a result, she has what she calls an “unusual relationship to death”. She created Edge of Life as a direct challenge to the “death-denying” culture of the West. The documentary focuses on two Australian palliative care doctors – Margaret Ross and Justin Dwyer. The pair carried out a successful 3-year trial using psilocybin-assisted therapy to provide what they describe as “rapid and sustained reductions in depression and anxiety” for terminally ill patients.

The documentary follows Wallworth to the Brazilian Amazon, where she connects Ross and Dwyer with the Yawanawá shamans, with whom she had worked previously. She convinced the doctors of the value of the indigenous knowledge that the Brazilian shamanic tradition could provide them. They have used the psychedelic, DMT-containing ayahuasca for millennia to ease the process of dying, embracing death as part of a natural journey. The film contrasts the two cultures, with the Western doctors progressively realising that their own medical language is not sufficient to describe these experiences.

One of the shamans, Muka, says that the film is a “generous gift” that supports indigenous culture, bringing their vital knowledge to the forefront, planting “seeds…in everyone’s heart.”

Psilocybin More Than Medicine?

A recent article in Reason has argued that considering psilocybin as solely a psychiatric medication is a flawed view. The reasoning behind this view is that it completely ignores the current (and historical) real-world uses of the substance and fails to address the injustices and illogicalities of prohibition. The author, Jacob Sullum, points to a 2023 RAND Corporation survey, which showed that the primary reasons that people actually use psilocybin will “never be approved by the FDA.

The survey showed that, while “improved mental health” was one goal for 49% of participants, the most common motivation was in fact “fun” (59% of participants). “Spiritual growth” (41%) and “personal development” (45%) were also cited as reasons for psilocybin use. Sullum concludes that this shows the medical-only path for integrating psilocybin into society is flawed. If governments criminalise the majority of psilocybin, or psychedelic use as a whole, simply because they deem it frivolous, this is not, in fact, providing either justice or an effective means of controlling the use of the substance. When individuals continue to be criminalised for personal choices, which can still potentially lead to lengthy prison sentences, Sullum argues that there needs to be a far wider consideration of the acceptable avenues of use.

Psychedelics and Neuroplasticity

Most research into psychedelics suggests they produce their seemingly long-lasting antidepressant effects as a result of their “psychoplastogenic” (new growth) effects. A new study, published in Neuropsychopharmacology, suggests that these effects are not in fact dependent upon structural plasticity. The study showed that a single dose of either psilocybin or another novel compound, 25CN-NBOH, produced antidepressant effects for at least three months. These effects were not accompanied by any corresponding changes in the physical structure of the affected areas of the brain.

Rather, the researchers suggest that these enduring benefits following treatment are a result of “functional plasticity” rather than structural. Months after the single dose, neurons in the medial prefrontal cortex (an area of the brain crucial for integrating new information, emotional regulation, and self-referential thinking) showed significant changes in their electrical properties. This indicates “functional plasticity”, a change in how the circuits themselves function, rather than a change in their construction.

The study reinforces the central role of the 5-HT2A serotonin receptors as largely responsible for the effects of psychedelic substances. The fact that both psilocybin, a well-known “classic” psychedelic, and 25CN-NBOH, a novel and highly selective 5-HT2A agonist (stimulates production at the receptor), exhibit similar antidepressant properties, suggests that stimulation of the 5-HT2A receptor is key to these effects. This discovery appears to alter the landscape of our understanding somewhat, away from a purely structural model to one more focused on alterations to functions within that existing structure.

Methylone and PTSD

The Mirabilis Health Institute, in County Antrim, is the only facility in Northern Ireland currently conducting trials into the therapeutic use of psychoactive substances. They are facing unprecedented levels of demand, with hundreds of people reportedly on the waiting list. The clinic is researching the effectiveness of psychoactive-assisted treatment for chronic conditions like PTSD. This is particularly relevant for a country like Northern Ireland, which one source in the Irish News described as a “pretty traumatised population.

The current trial focuses on methylone, a fairly recent, non-hallucinogenic compound, for treating post-traumatic stress disorder. The study, a first for Northern Ireland, will test both the efficacy and safety of the potential treatment. Participants will receive 4 weekly sessions, followed by a 6-week follow-up period to monitor the continued effects.

Professor Paul Miller, the doctor leading the study, has emphasised the intensely debilitating effects of PTSD and the dire need for innovative treatment for a population in crisis. The exceedingly high demand and length of the current waiting list are a testament to this.

The Trump Administration Embraces Psychedelic Therapy

Top officials in the Trump administration, including Vice President JD Vance, and the (already mentioned) Health Secretary Robert R. Kennedy Jr., attended what was named a “Make America Healthy Again” (MAHA) summit. A prominent feature of this summit was a panel dedicated to psychedelic medicine. The session was titled “Psychedelic Medicine: The Next Frontier in Mental Health” and was led by Christian Angermayer, a prominent proponent of psychedelics. He has previously described their ability to “take away the fear”.

The inclusion of the topic is further high-profile evidence of the Trump administration’s seemingly rapidly growing interest in the therapeutic potential of these substances. The summit’s focus also shows a broader, coordinated push for psychedelic reform. Kennedy has himself stated that he is “absolutely committed” to expanding research efforts, particularly in the area of supporting veterans struggling with PTSD.

Harvard Law School Debates Legalisation

Further evidence of the rapidly thawing attitude towards psychedelics in the US comes from Harvard Law School. A multidisciplinary panel of academics, experts, and advocates have met to discuss the potential for future federal legalisation of various psychedelic therapies.

The discussion focused on the myriad benefits of psychedelics for trauma recovery and mental health support, along with the necessity for effective FDA oversight. The experts also highlighted the key tensions across the field, with contrasting cultural attitudes towards drug use as a whole, as well as the lack of reliable data, which is still in comparatively “short supply”. David B. Yaden, a psychedelics researcher from Johns Hopkins, emphasised the necessity for large-scale, government-funded clinical trials. Holly Fernandez Lynch, a medical expert, also pushed the fact that psychedelics must be held to exactly the same FDA standards as other medications. Finally, Cat Packer of the Drugs Policy Alliance explained how the War on Drugs has had a powerfully negative impact on drug users and society as a whole. She emphasised the need for a completely new policy framework to account for the burgeoning psychedelic renaissance in a safe, sustainable manner.

David Blackbourn | Community Blogger at Chemical Collective

David is one of our community bloggers here at Chemical Collective. If you’re interested in joining our blogging team and getting paid to write about subjects you’re passionate about, please reach out to Sam via email at samwoolfe@gmail.com

share your toughts

Join the Conversation.

0 Comments

Inline Feedbacks

View all comments

9 minute read

In his book The Weird and the Eerie, cultural theorist Mark Fisher analyses the concept of the 'weird'. Sam Woolfe applies Fisher's analysis to psychedelic states.

09 Feb, 2026

Opinion | Psychedelics and Mark Fisher’s Theory of the Weird

Sam Woolfe

13 minute read

Un aperçu objectif du protoxyde d'azote, examinant sa normalisation croissante, ses effets puissants, son attrait, ses risques et son histoire.

07 Feb, 2026

Guides | Le gaz hilarant : Le protoxyde d’azote (N2O)

Nuit

13 minute read

Nuit compare les expériences de LSA issues de deux sources de semences, contextualisées par l'histoire et la science, dans le but de présenter une vision équilibrée des effets variables, des incertitudes, des risques et des enseignements de la LSA.

05 Feb, 2026

Personal Stories | Le LSA : la version naturelle du LSD ?

Nuit

12 minute read

Stroke, traumatic brain injury, and neurodegenerative diseases are leading, interconnected causes of global disability and economic burden with limited effective treatments. Sam Gandy highlights the potential of psychedelics as novel therapies to promote brain repair and recovery.

03 Feb, 2026

Science | Can Psychedelics Help Mend Broken and Ailing Brains?

Sam Gandy

11 minute read

The ancient, subterranean networks of fungi underpin life on Earth and are now emerging as a powerful foundation for future sustainable biotechnologies.

01 Feb, 2026

Science | Beyond the Trip: How Fungi Are Engineering Our Future

David Blackbourn

8 minute read

Dans la deuxième partie de ce guide sur l'influence du dosage sur les expériences psychédéliques, Eliacide examine les combinaisons de drogues et les expériences qui ne visent pas à dissoudre l'ego.

30 Jan, 2026

Guides | L’influence du dosage sur les expériences psychédéliques (Partie 2)

Eliacide

9 minute read

Eliacide explique que le dosage des médicaments est très subjectif et doit être choisi en fonction du niveau d'expérience personnel et du contexte souhaité, avertissant que les débutants doivent éviter les doses élevées et encourageant les individus à trouver leur propre « juste milieu » plutôt que de considérer tout conseil comme absolu.

28 Jan, 2026

Guides | L’influence du dosage sur les expériences psychédéliques (Partie 1)

Eliacide

9 minute read

Real-world data confirms the extremely low physical risk of psychedelics; the NHS and FDA intensify their scrutiny of clinical rollout; and we see expanding legal momentum in the US, as well as a shift towards shorter-acting compounds and even non-hallucinogenic, virtual alternatives.

26 Jan, 2026

All Articles | PSYCH NEWS – 26/01/2026

David Blackbourn

12 minute read

Nuit s'entretient avec Andrés Gómez, chercheur en conscience à l'Institut de recherche Qualia, qui fait le lien entre la science informatique, les récits expérientiels, les traditions contemplatives orientales et la recherche psychédélique.

25 Jan, 2026

Personal Stories | Mon échange avec le chercheur Andrés Gómez Emilson

Nuit

10 minute read

John Robertson offers a practical guide to understanding the causes of non-responses to psychedelics and what to do to move beyond them safely and effectively.

24 Jan, 2026

Guides | The ‘Nada’ Experience: What To Do When Psychedelics Don’t Work (Part 2)

John Robertson

7 minute read

Alfredo Squillaro argues that informed use, drug checking, and education are far more effective than stigma and repression in reducing the risks of psychoactive substance use.

22 Jan, 2026

Opinion | (Anti)prohibition, Psychonautics, and Designer Drugs

Alfredo Squillaro

11 minute read

Oli Genn-Bash reflects on the Western pursuit of an “authentic self,” using personal psychedelic experiences to question whether self-discovery is less about uncovering a fixed identity and more about cultivating a healthy relationship with the self that allows it to soften, open, and connect with others.

20 Jan, 2026

Self-Development | Discovering the Authentic Self Through Psychedelics

Oli Genn-Bash

9 minute read

Free parties can be understood as modern expressions of ancient ritual practices – akin to the Dionysian Mysteries – where music, dance, and psychoactive substances induce ecstatic states of consciousness.

18 Jan, 2026

Opinion | Dionysian Cults and Free Parties

Alfredo Squillaro

13 minute read

Nuit décrit son expérience du 2C-P comme un psychédélique puissant, à action lente et prolongée, appartenant à la famille des 2C-x – davantage comparable à une longue et exigeante randonnée qu'à un simple voyage.

16 Jan, 2026

Personal Stories | 2C-P : La charrette psychédélique

Nuit

11 minute read

Can psychedelics genuinely challenge and undermine the military-industrial complex by transforming consciousness, or do they risk being co-opted to merely help individuals psychologically adapt to an inherently violent and unjust system?

14 Jan, 2026

Opinion | Decentralised Minds: Can Psychedelics Undermine the Military Industrial Complex?

Oli Genn-Bash

11 minute read

Oli Genn-Bash explores the growing popularity of functional mushrooms, blending personal experience, research, and traditional perspectives to argue for a more holistic, respectful understanding of fungi.

12 Jan, 2026

Opinion | A Holistic and Spiritual Approach to Functional Mushrooms

Oli Genn-Bash

11 minute read

Despite bold promises surrounding psychedelics, a significant share of patients fail to meaningfully improve, revealing that non-response is a central – and often overlooked – challenge in psychedelic therapy.

10 Jan, 2026

Science | Let’s Talk About Non-Responders in Psychedelic Therapy

Ed Prideaux

8 minute read

Psychedelic use is commonly divided into spiritual, therapeutic, and recreational categories whose meanings are unclear and unevenly valued, with recreational use often stigmatised despite having aspects that deserve reconsideration.

08 Jan, 2026

Opinion | In Defence of Recreational Psychedelic Use

Annabelle Abraham

15 minute read

The Immortality Key builds a sweeping psychedelic-religion narrative on evidence that its own primary scientific authority later rejected as methodologically flawed, undermining the book’s credibility despite its popular success.

06 Jan, 2026

History | Psychedelic Bullshit? An Evaluation of The Immortality Key

Ed Prideaux

10 minute read

Over the past year, the psychedelic field has seen unprecedented scientific and regulatory advances collide with bureaucratic barriers and venture capital pressures, revealing both rapid progress toward medical integration and the fragility – and cultural tension – of an emerging industry at a pivotal moment.

04 Jan, 2026

News & Updates | PSYCH NEWS 2025 – THE YEAR IN REVIEW

David Blackbourn

8 minute read

Martha Allitt unpacks the history of MK-ULTRA, a secret CIA program that conducted unethical experiments with LSD, hypnosis, and other techniques in an attempt to develop methods of mind control and psychological manipulation during the Cold War.

04 Jan, 2026

History | MK-ULTRA: A Macabre History of LSD and Mind Control

Martha Allitt

16 minute read

Ed Prideaux examines Elon Musk’s alleged drug use and public behaviour in the context of his immense political and technological influence.

02 Jan, 2026

Opinion | High on Power: How Much Does Ketamine Explain Elon Musk’s Erratic Behaviour?

Ed Prideaux

10 minute read

Psychedelics can help us rethink the “hard problem” of consciousness by challenging the materialist view that the brain generates experience.

30 Dec, 2025

Philosophy | Psychedelics and the Hard Problem of Consciousness

David Blackbourn

12 minute read

Nuit décrit le 2C-C comme un membre subtil et apaisant de la famille 2C-X, qui évoque de doux souvenirs d'expériences sereines et introspectives.

28 Dec, 2025

Guides | 2C-C : la version Stone du 2C-B ?

Nuit

4 minute read

Theories suggest that N,N-dimethyltryptamine (DMT) is released in our brains when we die – but what do we really know about this potent psychedelic and its endogenous role in the human body?

22 Dec, 2025

Science | The Endogenous DMT Narrative: Separating Fact From Fiction

Stephanie Price

11 minute read

While psychedelics get most of the limelight in discussions about altered states of consciousness, such states can also be accessed through more accessible and potentially safer means, particularly sound baths.

20 Dec, 2025

Spirituality | Sound Baths and Altered States

Oli Genn-Bash

9 minute read

David Blackbourn explores the history and present-day use of psychoactive substances in the Middle East, including the religious, social, and political factors that have influenced this usage.

18 Dec, 2025

History | Contemporary Psychoactive Drug Use in the Middle East

David Blackbourn

8 minute read

Iboga, a West African shrub traditionally used in the Bwiti spiritual tradition, is now being used for microdosing in the West.

16 Dec, 2025

Personal Stories | Microdosing Iboga: Why People Are Taking Tiny Amounts of a Hallucinogenic Shrub

Martha Allitt

5 minute read

Clinical trials typically evaluate psychedelics through short-term before-and-after measures to assess treatment efficacy, but longer-term and lifelong effects are harder to quantify.

14 Dec, 2025

Self-Development | The Long-Term Effects of Psychedelics Are Sometimes Ambiguous

Annabelle Abraham

11 minute read

While psychedelic insights may be valuable, they can be difficult to interpret and require a broader psychological, spiritual, philosophical, or cultural framework to determine whether they reflect genuine truth or mere subjective experience.

12 Dec, 2025

Self-Development | Psychedelics and Epistemic Authority: How Can We Trust Psychedelic Insights?

Oli Genn-Bash

Our Products

Related Products

SALE! -35%

1V-LSD 150mcg Blotters From

(145)

1cP-LSD 100mcg Blotters From 18.00

(137)

Tryptamine Mix and Match Pack (4 x 0.1g) €65.00

(1)

SALE! -35%

1V-LSD 10mcg Micro Pellets From

(44)

SALE! -35%

1V-LSD 225mcg Art Design Blotters From

(62)

1S-LSD 150mcg Blotters From 29.00

(18)

1cP-LSD 150mcg Art Design Blotters From 25.00

(74)

SALE! -35%

1V-LSD 225mcg Pellets From

(26)

1cP-LSD 10mcg Micro Pellets From 15.00

(23)

1D-LSD 225mcg Pellets (1T-LSD) From 42.00

(13)

5-MeO-DMT Freebase From 23.95

(36)

1S-LSD 10mcg Micro Pellets €20.00

(3)

O-PCE HCL From 17.50

(25)

1cP-LSD 20mcg Micro Blotters From 18.00

(28)

1cP-LSD 150mcg Pellets From 25.00

(13)

see all products

Earn
Affiliates

Welcome to Chemical Collective.

Create an account to earn 200 welcome points.

create account

Already have an account? Sign in

Comment on an article

50

Check out our Community Blog and get involved with the conversation. You will be awarded 50 x ChemCoins for each comment up to a limit of 250 total ChemCoins.
Leave a product review

50

Have you purchased any of our products? Reviews and reports are so important to the community. Share your honest opinion, and we’ll reward you with 50 ChemCoins for each review!
Complete an order

X

Every time you complete an order with us, you’ll be awarded ChemCoins for each Euro spent.

Welcome to Chemical Collective.

Create an account to earn 200 welcome points.

create account

Already have an account? Sign in

Become an affiliate!

Earn commission every time someone makes a purchase through your link.

When you become an affiliate, you will be allocated a unique link to share with your friends, followers, subscribers, or Aunt Susan.

You can choose to payout the commission earned once per month, or save it up to receive on a rainy day! Commission earned is 5% of the total order value per referral.

Contact us to join the Chemical Collective family and become an affiliate.

Welcome toChemical Collective

PSYCH NEWS – 17/11/25

By David Blackbourn

in this article

By David Blackbourn

LSD and Major Depressive Disorder

Robert F. Kennedy Jr. Smokes DMT?

25C-NBF is a Rapid Antidepressant

Not Just a Running Documentary: Dante

Psychedelic Therapy: Edge of Life

Psilocybin More Than Medicine?

Psychedelics and Neuroplasticity

Methylone and PTSD

The Trump Administration Embraces Psychedelic Therapy

Harvard Law School Debates Legalisation

By David Blackbourn

share your toughts

Join the Conversation.

Related articles

Related Products

Reward program

Comment on an article

Leave a product review

Complete an order

Become an affiliate!

Welcome to
Chemical Collective